Neulasta and Rabeprazole sodium drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neulasta (pegfilgrastim) and Rabeprazole sodium (rabeprazole sodium). Common drug interactions include coma among females and chest pain among males.

The phase IV clinical study analyzes what interactions people have when they take Neulasta and Rabeprazole sodium. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Rabeprazole sodium?

Rabeprazole sodium has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 15,786 Rabeprazole sodium users. Check the latest studies of Rabeprazole sodium.



On Jul, 19, 2026

12 people who take Neulasta and Rabeprazole sodium together, and have interactions are studied.

Neulasta and Rabeprazole sodium drug interactions.

What are the common drug interactions of Neulasta and Rabeprazole Sodium, by gender? *:

female:

  1. Coma (state of unconsciousness lasting more than six hours)
  2. Pleural effusion (water on the lungs)
  3. Respiratory failure (inadequate gas exchange by the respiratory system)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Abdominal discomfort
  6. Abdominal distension
  7. Abdominal pain
  8. Anxiety
  9. Ascites (accumulation of fluid in the abdominal cavity)
  10. Asthenia (weakness)

male:

  1. Chest pain
  2. Heart rate increased
  3. Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously)

What are the common drug interactions of Neulasta and Rabeprazole Sodium, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  2. Diarrhoea
  3. Drug ineffective
  4. Neuropathy peripheral (surface nerve damage)
  5. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  6. Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
  7. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  8. Sinusitis (inflammation of sinus)
  9. White blood cell count decreased

60+:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Mucosal inflammation (infection of mucous membrane)
  3. Colon adenoma (non cancerous epithelial colon tumour having a glandular origin and structure)
  4. Colonic polyp (extra part of colon tissue grow in intestine)
  5. Confusional state
  6. Drug hypersensitivity
  7. Fatigue (feeling of tiredness)
  8. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  9. Hepatomegaly (abnormal enlargement of the liver)
  10. Hypokalaemia (low potassium)

What are the existing conditions these people have? *

  1. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 16.67%
  2. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 16.67%
  3. Pre-Existing Disease: 1 person, 8.33%
  4. Pain: 1 person, 8.33%
  5. Osteoporosis (bones weak and more likely to break): 1 person, 8.33%
  6. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 8.33%
  7. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 8.33%
  8. Lymphoma (cancer that begins in immune system cells): 1 person, 8.33%
  9. Breast Cancer: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and Rabeprazole sodium?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Neulasta and Rabeprazole sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rabeprazole sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neulasta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rabeprazole sodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim and rabeprazole sodium (the active ingredients of Neulasta and Rabeprazole sodium, respectively), and Neulasta and Rabeprazole sodium (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: